Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134725) titled 'Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG' on Aug. 19.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Federal University of Minas Gerais
Condition:
COVID - 19
Intervention:
Biological: SpiN-Tec MCTI UFMG
Other: Active Comparator: Covishield(R) vaccine
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: November 23, 2022
Target Sample Size: 432 ...